

## ASX Release

# Anatara Investor Presentation

BRISBANE, 29th July 2019: Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the 15<sup>th</sup> Bioshares Biotech Summit, held in Queenstown, New Zealand, 26<sup>th</sup> to 27<sup>th</sup> July 2019.

A copy of the presentation is attached.

### For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

### About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.


### Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



# Bioshares 2019

## Gut health and the microbiome




# No guts, no glory: why microbiome is so hot right now!

Up to 90% of all **disease** can be traced back to **the gut** and the health of the microbiome



**10-100 TRILLION**<sup>1</sup>

Number of **microbial cells** harboured by each person that make up the human microbiome



**95%**

of your **bacteria** is located in your **gastrointestinal tract**

**100 to 1**<sup>1</sup>

the **genes in our gut microbiome** outnumber the genes in our genome by approximately **100 to 1**



# Microbiome research is changing medicine

## *Nature*<sup>2</sup> says

According to *Nature*, **\$1.7 billion** has been spent on microbiome research in the last 10 years

## A huge market

The global market for human microbiome-based drugs and diagnostics should reach a market size of nearly **\$9.9 billion by 2024\***

## The road ahead

An area of growing interest, microbiome-based research is changing the way we treat a wide range of diseases

# Our place in the microbiome treatment landscape

Identifying a specific bacterial strain, or group of strains, that is delivered alive to the patient's gut



Drugs that specifically target the bacteria that cause disease while leaving the rest of the gut microbiome intact



ANATARA  
LIFESCIENCES



C3J Therapeutics



SECOND GENOME

Fecal microbiota treatment (FMT)



Bacteriophages



BiomX

CRISPR/Cas9




Engineering bacteria to become drug factories directly within the human gut


Anaeropharma Science



# Microbiome: broad indications and health opps



# Burgeoning market: our first targets






*IBS is the **most commonly diagnosed gastrointestinal condition** and a significant cost burden on health care<sup>3</sup>*

# IBS in a minute

# 11%

IBS affects around 11% of the global population<sup>4</sup>



It costs around **\$21billion** or more annually in direct medical costs and absenteeism<sup>5</sup>



Patients have a **poor quality of life** and **use healthcare system more than other patients**



IBS is a functional disorder, requiring **management of symptoms** such as **pain, bloating and alternating constipation and diarrhoea**



**50%** of patients turn to dietary supplements and complementary medicines<sup>6</sup>

# Profound impact on patients

*"Imagine a day where you fell ill from having eaten too much, then imagine that day lasts **months at a time.**"*

Australian IBS patient<sup>7</sup>

# IBS - one of the most burdensome chronic ailments reported by patients<sup>8</sup>



Individuals with IBS restrict their activities an average of

**73 DAYS** a year<sup>8</sup>



**45%** of IBS-D\* patients agreed with the statement

*"I'm willing to try anything to help manage my IBS"*<sup>9</sup>



Patients reported they would give up

**25%** of their remaining life (approx. 15 years)<sup>9</sup>



**14%** said they would risk a **1/1000 chance of death** to live symptom-free<sup>9</sup>

\* IBS-D = Irritable Bowel Disease - Diarrhoea Predominant

# USA gastrointestinal health market

## US \$8b

USA digestive remedies and GI supplement sales



## 8/10

Adults suffer annually from a digestive issue<sup>10</sup>



## US\$5b

OTC\*\* digestive remedies 2018<sup>10</sup>



## US\$3b

GI\* supplement sales 2018<sup>11</sup>



## ↑ 11.9%

OTC\*\* digestive remedies over the past 5 years<sup>10</sup>

\* GI = Gastrointestinal

\*\* OTC = over-the-counter

# Global consumer health market opportunity

**US \$5.7b**

Global probiotic supplement sales<sup>12</sup>

## Probiotic supplements



Align® (P&G) sales  
(U.S.) 2018:  
**US\$171.9m<sup>12</sup>**

## Other GI supplements



Iberogast® (Bayer) sales  
(Germany) 2018:  
**US\$145m<sup>12</sup>**


## OTC digestive supplements




Buscopan® (Sanofi) sales  
(Global) 2018:  
**US\$220m<sup>13</sup>**

(OTC only, excludes prescription sales)

# 3 primary underlying factors of IBS and IBD



# How are these addressed?




\***G**astrointestinal **R**eProgramming (**GaRP**) dietary supplement

# Changing the game for IBS

## GaRP dietary supplement

- Regenerative, multi-component dietary supplement
  - Dual targeted formulation (small intestine and colon)
- Positioned as either an adjunct to existing therapies, or a sole therapy for IBS
- Designed to address 3 primary underlying factors associated with gastrointestinal disorders such as IBS and IBD
  - Strong pre-clinical evidence




# Assumption or fact?

## Anatara's Approach: evidence-based complementary medicine

- Most complementary medicines are listed, **not registered medicines**
- No requirement for own safety or efficacy studies for listed medicines
- **Anatara's approach is to develop its own evidence for safety and efficacy**
  - Pre-clinical *in vitro* models were used to determine likely impact on efficacy for each ingredient
  - Both *in vivo* animal models and a human clinical study will be used to demonstrate formulation safety and efficacy



# Grounded in scientific evidence



Successful Proof of Concept Studies (February 2019)  
 Demonstrated using industry-standard *in vitro* gut models

# Next steps: human trial

- **Pre-clinical animal studies** are currently underway where GaRP is being evaluated in a model representative of IBD
  - Data expected Q4 2019
- Pre-trial activities for a **human clinical study** in IBS patients have commenced, with a view to study initiation late 2019
- **Partnering discussions** to commence upon completion of pre-clinical animal studies **Q4 2019**
- View to a **partnering deal** by **mid 2020**



# Future opportunities

Anatara has the potential to leverage and apply the proprietary know-how and IP created through the development of our GaRP dietary supplement into other gastrointestinal diseases that are caused by a disrupted microbiome, inflammation and mucosal damage such as:


- **Functional Dyspepsia**
- **Small Intestinal Bacterial Overgrowth (SIBO)**



# Bringing science to supplements

- **Evidence-based** breakthrough product for IBS and IBD
  - Patentable multi-component, dual-targeted formulation
  - Delivers the components where they can be most effective
- Fewer or lower regulatory requirements than pharmaceuticals<sup>14</sup>
  - **Lower development cost**
  - **Lower development risk**
  - **Faster time to market**
- **Swift timeframe (18 – 24 months) to partnering milestone**





## Contact Anataro Lifesciences Ltd

Steven Lydeamore, CEO

+61 438 027 172

[slydeamore@anataro.com](mailto:slydeamore@anataro.com)

[www.anatarolifesciences.com](http://www.anatarolifesciences.com)

@AnataroANR



[anataro-lifesciences-ltd](https://www.linkedin.com/company/anataro-lifesciences-ltd)

